Subtype
Prostate Carcinoma
CI-CAN-00006533Explore in graph →
430 active trials16 approved drugs20 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00006533Explore in graph →
Clinical trials
1,177 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (184)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03437941 | Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 39 | Corcept TherapeuticsINDUSTRY | 2 | May 15, 2026 | clinicaltrials |
| NCT04472338 | Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study | recruiting | — | 450 | University of WashingtonOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT04716725 | 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer | terminated | Phase 2 | 15 | Thomas HopeOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT05627219 | Extending Prostate Genetic Awareness, Navigation, and Delivery: The EXPAND Network | recruiting | — | 30 | Thomas Jefferson UniversityOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT06691984 | Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute) | active not recruiting | Phase 3 | 707 | AmgenINDUSTRY | 22 | May 15, 2026 | clinicaltrials |
| NCT07093801 | Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer | recruiting | — | 300 | Novartis PharmaceuticalsINDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT07244341 | A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC) | recruiting | Phase 1 | 60 | Daiichi SankyoINDUSTRY | 4 | May 15, 2026 | clinicaltrials |
| NCT07476001 | Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC | recruiting | Phase 2 | 12 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT02312557 | Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide | active not recruiting | Phase 2 | 58 | OHSU Knight Cancer InstituteOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT04030559 | Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects | terminated | Phase 2 | 11 | University of California, DavisOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT04769817 | ProsTIC Registry of Men Treated With PSMA Theranostics | active not recruiting | — | 500 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT05413850 | Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection | recruiting | Phase 1 / Phase 2 | 82 | Blue Earth Therapeutics LtdINDUSTRY | 5 | May 14, 2026 | clinicaltrials |
| NCT06733350 | Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance | recruiting | Phase 4 | 600 | Roswell Park Cancer InstituteOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT04314401 | National Cancer Institute "Cancer Moonshot Biobank" | active not recruiting | — | 1,600 | National Cancer Institute (NCI)NIH | 2 | May 13, 2026 | clinicaltrials |
| NCT04955808 | Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery | suspended | — | 2,400 | National Cancer Institute (NCI)NIH | 1 | May 13, 2026 | clinicaltrials |
| NCT07583160 | YS247 (Neoantigen-Pulsed DC Vaccine) for Metastatic Prostate Cancer(YS247) | enrolling by invitation | Phase 1 | 18 | Changhai HospitalOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT02761889 | Hypofractionated Image-Guided Radiotherapy (IGRT) With Organ Motion Mitigation and Urethral Sparing for Prostate Cancer | completed | N/A | 444 | Fundacao ChampalimaudOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT04846478 | Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC | active not recruiting | Phase 1 | 35 | Dana-Farber Cancer InstituteOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT06879041 | A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 | 136 | AstraZenecaINDUSTRY | 3 | May 12, 2026 | clinicaltrials |
| NCT04384770 | CT-guided Stereotactic Body Radiation Therapy and MRI-guided Stereotactic Body Radiation Therapy for Prostate Cancer, MIRAGE Study | active not recruiting | — | 179 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04486755 | Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048) | active not recruiting | Phase 1 | 18 | University of Maryland, BaltimoreOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04986423 | ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 2 | 200 | Zenith EpigeneticsINDUSTRY | 2 | May 8, 2026 | clinicaltrials |
| NCT06011499 | Internet-Based Lifestyle Intervention to Eradicate Obese Frailty in Prostate Cancer Survivors, iLIVE(iLIVE) | recruiting | N/A | 250 | OHSU Knight Cancer InstituteOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07025512 | 177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | May 8, 2026 | clinicaltrials |
| NCT07414940 | ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium(ACT-RESoLUTE) | recruiting | Phase 1 / Phase 2 | 60 | University College, LondonOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT03880422 | Nutrition and Exercise Interventions for Androgen Deprivation Therapy-Induced Obese Frailty in Elderly and Non-Elderly Survivors of Advanced Prostate Cancer | recruiting | N/A | 50 | Roswell Park Cancer InstituteOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT03123978 | Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 | 6 | University of California, DavisOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07504835 | GET FIT Together: Testing a Socially Enhanced Exercise Program in Older Men With Prostate Cancer | recruiting | N/A | 150 | OHSU Knight Cancer InstituteOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07568756 | Utilization of Flotufolastat 18F PET for Post-Focal Therapy Prostate Cancer Evaluation | not yet recruiting | Phase 2 | 60 | University of California, IrvineOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT01411345 | MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial(MAPS) | active not recruiting | N/A | 37 | University of MiamiOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03217747 | Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies | active not recruiting | Phase 1 / Phase 2 | 173 | M.D. Anderson Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05005728 | XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 72 | Xencor, Inc.INDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT05125016 | A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer | recruiting | Phase 1 / Phase 2 | 228 | Regeneron PharmaceuticalsINDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT06616155 | Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 / Phase 2 | 20 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03772834 | Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients With Prostate Cancer | active not recruiting | Phase 2 / Phase 3 | 200 | M.D. Anderson Cancer CenterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05362032 | Feasibility of OmnEcoil System for Integrated Endorectal MRI and Transrectal MRI-Targeted Biopsy of the Prostate | suspended | N/A | 45 | OHSU Knight Cancer InstituteOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05851365 | Magnetic Resonance (MR) Imaging With Hyperpolarized Bicarbonate (13C) to Measure Tissue pH in Prostate Cancer | active not recruiting | Early Phase 1 | 1 | Robert Flavell, MD, PhDOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT02526368 | Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer | recruiting | Early Phase 1 | 80 | Ivan de Kouchkovsky, MDOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07451795 | SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC(SHARP) | recruiting | Phase 2 | 66 | Fudan UniversityOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT03218826 | PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 23 | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07052760 | Imaging of Solid Tumors Using DLL3 SPECT | withdrawn | Early Phase 1 | 0 | Thomas HopeOTHER | 0 | Apr 29, 2026 | clinicaltrials |
| NCT06630325 | A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer | terminated | Phase 2 | 6 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07553988 | A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer | active not recruiting | Phase 2 | 120 | R-Pharm International, LLCINDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT04465500 | EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer(Prostate005) | active not recruiting | Phase 2 | 60 | University of VirginiaOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT05588609 | Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers | terminated | Phase 2 | 13 | Partner Therapeutics, Inc.INDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06104449 | A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005) | completed | Phase 1 | 7 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06242509 | Intestinal Akkermansia Muciniphila in Prostate Cancer(AkkPRO) | recruiting | — | 52 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06580015 | [18F]-rhPSMA PET-CT Imaging Performance in Patients With Prostate Cancer | active not recruiting | N/A | 20 | City of Hope Medical CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT03522064 | Bipolar Androgen Therapy + Carboplatin in mCRPC(HiTeCH) | recruiting | Phase 2 | 30 | St Vincent's Hospital, SydneyOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT03682289 | Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors | active not recruiting | Phase 2 | 83 | Rahul AggarwalOTHER | 1 | Apr 23, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 15, 2026source: clinicaltrials